Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review.

[1]  Thalia Shoshana Field,et al.  Off-label use of novel anticoagulants for treatment of cerebral venous thrombosis: A Canadian survey , 2017, International journal of stroke : official journal of the International Stroke Society.

[2]  P. Noseworthy,et al.  Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. , 2017, Gastroenterology.

[3]  D. Isenberg,et al.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial , 2016, The Lancet. Haematology.

[4]  Luc Bressollette,et al.  Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France , 2016, Thrombosis and Haemostasis.

[5]  J. Eikelboom,et al.  Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. , 2016, Circulation research.

[6]  R. Evans,et al.  Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[7]  A. Gallus,et al.  Novel protein C gene mutation in a compound heterozygote resulting in catastrophic thrombosis in early adulthood: diagnosis and long‐term treatment with subcutaneous protein C concentrate , 2016, British journal of haematology.

[8]  V. Pengo,et al.  Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial , 2016, Lupus.

[9]  H. Mariz,et al.  Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases , 2016, Clinical Rheumatology.

[10]  W. Ageno,et al.  Guidance for the management of venous thrombosis in unusual sites , 2016, Journal of Thrombosis and Thrombolysis.

[11]  G. Tobón,et al.  Direct oral anticoagulants in antiphospholipid syndrome: a real life case series , 2016, Lupus.

[12]  J. Cha,et al.  Cerebral venous thrombosis in a patient with Crohn's disease , 2016, Intestinal research.

[13]  A. Iorio,et al.  Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials , 2015, Journal of thrombosis and haemostasis : JTH.

[14]  Raquel Barbosa,et al.  Oral Direct Thrombin Inhibitor as an Alternative in the Management of Cerebral Venous Thrombosis: A Series of 15 Patients , 2015, International journal of stroke : official journal of the International Stroke Society.

[15]  R. Behrouz,et al.  Rivaroxaban for the treatment of cerebral venous thrombosis , 2015, International journal of stroke : official journal of the International Stroke Society.

[16]  A. Di Minno,et al.  Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. , 2015, Blood reviews.

[17]  W. Ageno,et al.  Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. , 2015, JAMA internal medicine.

[18]  S. Calleja,et al.  Antiphospholipid Syndrome of Late Onset: A Difficult Diagnosis of a Recurrent Embolic Stroke. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[19]  J. Piette,et al.  Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. , 2015, Autoimmunity reviews.

[20]  A. Mekaj,et al.  New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events , 2015, Therapeutics and clinical risk management.

[21]  S. Sciascia,et al.  Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. , 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  D. Isenberg,et al.  Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE , 2015, Lupus.

[23]  A. Undas,et al.  The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. , 2015, Thrombosis research.

[24]  N. Abraham,et al.  Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study , 2015, BMJ : British Medical Journal.

[25]  S. Caldwell,et al.  Treating thrombosis in cirrhosis patients with new oral agents: Ready or not? , 2015, Hepatology.

[26]  K. Lenz,et al.  Successful Treatment of Partial Portal Vein Thrombosis (PVT) with Low Dose Rivaroxaban , 2014, Zeitschrift für Gastroenterologie.

[27]  G. Rodgers,et al.  New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome , 2014, American journal of hematology.

[28]  C. Bachmeyer,et al.  Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome , 2014, Clinical and experimental dermatology.

[29]  K. Moder,et al.  Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients , 2014, Thrombosis and Haemostasis.

[30]  S. Nagel,et al.  Novel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis: First Experience in 7 Patients , 2014, Stroke.

[31]  A. Undas,et al.  PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. , 2014, Thrombosis research.

[32]  P. García de Frutos,et al.  Protein S deficiency and novel oral anticoagulants: an intriguing case. , 2014, Thrombosis research.

[33]  W. Jehangir,et al.  Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature , 2014 .

[34]  T. Ortel,et al.  14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. , 2014, Autoimmunity reviews.

[35]  D. Horton,et al.  Rivaroxaban for the Long-term Treatment of Spontaneous Ovarian Vein Thrombosis Caused by Factor V Leiden Homozygosity , 2014, The Annals of pharmacotherapy.

[36]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[37]  R. Cervera,et al.  Diagnosis and classification of the antiphospholipid syndrome. , 2014, Journal of autoimmunity.

[38]  J. Beyer-Westendorf,et al.  Increase of gastrointestinal bleeding with new oral anticoagulants: problems of a meta-analysis. , 2013, Gastroenterology.

[39]  I. Martinelli,et al.  Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency , 2013, Pediatrics.

[40]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[41]  G. Raskob,et al.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies , 2013, Thrombosis Journal.

[42]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[43]  E. Kuipers,et al.  New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. , 2013, Gastroenterology.

[44]  S. Goldhaber,et al.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.

[45]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[46]  M. Aramideh,et al.  The Incidence of Cerebral Venous Thrombosis: A Cross-Sectional Study , 2012, Stroke.

[47]  P. Cheng,et al.  Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[48]  R. Lecumberri,et al.  Discovery of anticoagulant drugs: a historical perspective. , 2012, Current drug discovery technologies.

[49]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[50]  C. Hermans,et al.  Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency , 2012, Thrombosis and Haemostasis.

[51]  J. Ferro,et al.  Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[52]  P. Groot.  Mechanisms of anti-phospholipid antibody formation and action. , 2011 .

[53]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[54]  A. Bergquist,et al.  The epidemiology and clinical features of portal vein thrombosis: a multicentre study , 2010, Alimentary pharmacology & therapeutics.

[55]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[56]  D. Valla,et al.  Vascular disorders of the liver , 2009, Hepatology.

[57]  E. Björnsson,et al.  Budd‐Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival – an 18‐year experience , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[58]  S. Acosta,et al.  Epidemiology, risk and prognostic factors in mesenteric venous thrombosis , 2008, The British journal of surgery.

[59]  E. Oger,et al.  Venous thromboembolism (VTE) in Europe , 2007, Thrombosis and Haemostasis.

[60]  J. Ferro,et al.  Cerebral venous thrombosis: an update , 2007, The Lancet Neurology.

[61]  Salwa Khan,et al.  Hereditary thrombophilia , 2006, Thrombosis journal.

[62]  R. Goldberg,et al.  The worcester venous thromboembolism study , 2006, Journal of General Internal Medicine.

[63]  M. Björck,et al.  Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. , 2006, World journal of gastroenterology.

[64]  J. Stam.  Thrombosis of the cerebral veins and sinuses. , 2005, The New England journal of medicine.

[65]  J. Ferro,et al.  Prognosis of Cerebral Vein and Dural Sinus Thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) , 2004, Stroke.

[66]  J. Levine,et al.  The antiphospholipid syndrome. , 2002, The New England journal of medicine.

[67]  F. Rosendaal.  Venous thrombosis: a multicausal disease , 1999, The Lancet.

[68]  S. Anticoli,et al.  Treatment of Cerebral Venous Thrombosis with Rivaroxaban , 2016 .

[69]  H. Ichikawa,et al.  Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid. , 2015, Internal medicine.

[70]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.